Jul 14, 2026 07:32AM
Jul 14, 2026 07:30AM
Jul 9, 2026 07:30AM
Jul 9, 2026 07:30AM
Jul 6, 2026 07:30AM
Jul 6, 2026 07:30AM
Jun 22, 2026 04:05PM CervoMed closes $10M stock offering at $4.00 per share
Jun 22, 2026 04:05PM
Jun 18, 2026 12:35PM
Jun 18, 2026 12:35PM
Jun 18, 2026 07:00AM
Jun 18, 2026 07:00AM
Jun 16, 2026 03:22PM
Jun 16, 2026 10:18AM Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum
Jun 12, 2026 07:30AM
Jun 10, 2026 07:30AM
Jun 10, 2026 07:30AM
May 18, 2026 07:30AM
Apr 22, 2026 07:30AM
Apr 7, 2026 07:30AM
Apr 7, 2026 07:30AM CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
Mar 19, 2026 07:31AM
Mar 19, 2026 07:30AM
Mar 17, 2026 07:30AM
Mar 12, 2026 07:00AM
Mar 4, 2026 07:30AM
Mar 4, 2026 07:30AM
Feb 18, 2026 06:02AM CervoMed's neflamapimod selected for UK ALS trial platform
Feb 18, 2026 06:00AM
Dec 4, 2025 05:00PM
Dec 4, 2025 05:00PM
Dec 2, 2025 07:01AM
Dec 2, 2025 07:00AM
Nov 24, 2025 07:00AM
Nov 10, 2025 07:00AM CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Nov 4, 2025 07:00AM
Nov 4, 2025 07:00AM
Oct 28, 2025 08:03AM
Oct 28, 2025 08:00AM
Oct 8, 2025 07:00AM
Oct 8, 2025 07:00AM
Oct 7, 2025 08:01AM CervoMed names Matthew Winton as chief commercial and business officer
Oct 7, 2025 08:00AM
Sep 17, 2025 07:30AM
Aug 11, 2025 08:00AM
Jul 28, 2025 07:01AM
Jul 28, 2025 07:00AM
Jun 10, 2025 08:00AM
May 12, 2025 03:57PM Chardan Capital Markets Reiterates Buy Rating on CervoMed (CRVO)
May 12, 2025 08:00AM

325,873 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All